SV

Street Verdict

Analyst Scorecard

A record of what Pankaj Pandey said publicly, with the source. Not advice.

Pending — not yet graded
“Bullish on Piramal Pharma, with its Contract Development and Manufacturing Organisation (CDMO) business performing well, contributing 54% of revenue and growing at 38%. The brokerage remains positive on the CDMO opportunity due to a large patent expiry cycle of nearly $135 billion over the next 4-5 years, creating a $300 billion opportunity size.”

Pankaj Pandey’s track record (trackable calls only): 18 graded calls · 95% CI 39–80%

Piramal Pharma LtdBullishCalled 28 Oct 2026
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Pankaj Pandey’s full track record